• Users Online: 51
  • Print this page
  • Email this page
CASE REPORT
Year : 2021  |  Volume : 15  |  Issue : 3  |  Page : 279-281

Pretransplant compatibility tests in kidney transplants: Significance of adding HLA bead-based assay to direct cell-based cross-match assays - A case report


Department of Transfusion Medicine, Molecular and Transplant Immunology Laboratory, Medanta-The Medicity, Gurgaon, Haryana, India

Correspondence Address:
Ms. Chhavi Rajvanshi
Department of Transfusion Medicine, Molecular and Transplant Immunology Laboratory, Medanta-The Medicity, Gurgaon, Haryana
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijot.ijot_54_20

Get Permissions

Pre-transplant compatibility work-up has evolved tremendously from conventional CDC only to CDC with more sensitive FCXM testing with bead-based assays (LMX and SAB). Detection of alloantibodies is one of the major objective in work-up algorithm. Conventionally cell-based tests were used, if both are negative, hospital usually proceeds for transplantation. If one of the screening tests (CDC/FCXM) is or both (CDC and FCXM) screening tests are positive, antibody identification is performed on Luminex platform to determine DSA by virtual cross-match. However, cell-based tests have their limitations. Here, we described a case which could have gone unnoticed if HLA bead-based assay was not there and could have triggered AMR (Antibody mediated rejection) as detected antibody (DRB1*07:01; BCM is 16416) was DSA.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed115    
    Printed4    
    Emailed0    
    PDF Downloaded14    
    Comments [Add]    

Recommend this journal